Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients

Journal of Infectious Diseases

Volumn 191, Issue 4, 2005, Pages 520-530

  Heemskerk, Bianca ^a   Lankester, Arjan C ^a   Van Vreeswijk, Tamara ^a   Beersma, Matthias F C ^a   Claas, Eric C J ^a   Veltrop Duits, Louise A ^a   Kroes, Aloys C M ^a   Vossen, Jaak M J J ^a   Schilham, Marco W ^a   Van Tol, Maarten J D ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CIDOFOVIR; CYCLOSPORIN A; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; NEUTRALIZING ANTIBODY; RIBAVIRIN; THYMOCYTE ANTIBODY; VIRUS ANTIBODY; VIRUS DNA;

ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; HUMAN ADENOVIRUS; HUMAN CELL; HUMORAL IMMUNITY; INFANT; LYMPHOCYTE COUNT; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT; T LYMPHOCYTE; VIREMIA; VIRUS INFECTION; VIRUS LOAD;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ADOLESCENT; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; FEMALE; HUMANS; INFANT; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; NEUTRALIZATION TESTS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL; VIRAL LOAD; VIREMIA;

EID: 13444256480     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/427513     Document Type: Article

References (53)

1. Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994; 169:775-81.
2. Childs R, Sanchez C, Engler H, et al. High incidence of adeno- and polyomavirus-induced hemorrhagic cystitis in bone marrow allotransplantation for hematological malignancy following T cell depletion and cyclosporine. Bone Marrow Transplant 1998; 22:889-93.
3. Hale GA, Heslop HE, Krance RA, et al. Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant 1999; 23:277-82.
4. Howard DS, Phillips II GL, Reece DE, et al. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 1999; 29:1494-501.
5. Baldwin A, Kingman H, Darville M, et al. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant 2000; 26:1333-8.
6. Runde V, Ross S, Trenschel R, et al. Adenoviral infection after allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a prospective multi center surveillance study. Bone Marrow Transplant 2001; 28:51-7.
7. Bruno B, Gooley T, Hackman RC, Davis C, Corey L, Boeckh M. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol Blood Marrow Transplant 2003; 9:341-52.
8. Walls T, Shankar AG, Shingadia D. Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients. Lancet Infect Dis 2003; 3:79-86.
9. Hierholzer J. Adenoviruses in the immunocompromised host. Clin Microbiol Rev 1992; 5:262-74.
10. De Jong JC, Wermenbol AG, Verweij-Uijterwaal MW, et al. Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin Microbiol 1999; 37:3940-5.
11. Carrigan DR. Adenovirus infections in immunocompromised patients. Am J Med 1997; 102:71-4.
12. Schilham MW, Claas EC, van Zaane W, et al. High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. Clin Infect Dis 2002; 35:526-32.
13. Lankester AC, van Tol MJ, Claas EC, Vossen JM, Kroes AC. Quantification of adenovirus DNA in plasma for management of infection in stem cell graft recipients. Clin Infect Dis 2002; 34:864-7.
14. Echavarria M, Forman M, van Tol MJ, Vossen JM, Charache P, Kroes AC. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet 2001; 358:384-5.
15. Lion T, Baumgartinger R, Watzinger F, et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 2003; 102:1114-20.
16. Leruez-Ville M, Minard V, Lacaille F, et al. Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection. Clin Infect Dis 2004; 38:45-52.
17. Gu Z, Belzer SW, Gibson CS, Bankowski MJ, Hayden RT. Multiplexed, real-time PCR for quantitative detection of human adenovirus. J Clin Microbiol 2003; 41:4636-41.
18. Hromas R, Cornetta K, Srour E, Blanke C, Broun ER. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T cell depleted bone marrow transplantation. Blood 1994; 84:1689-90.
19. Chakrabarti S, Collingham KE, Fegan CD, Pillay D, Milligan DW Adenovirus infections following haematopoietic cell transplantation: is there a role for adoptive immunotherapy? Bone Marrow Transplant 2000; 26:305-7.
20. + T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001; 98:1358-64.
21. Chakrabarti S, Milligan DW, Pillay D, et al. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 2003; 102:839-42.
22. + T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003; 101:4290-7.
23. Hakki M, Riddell SR, Storek J, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003; 102:3060-7.
24. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101:407-14.
25. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002; 100:1619-27.
26. Chakrabarti S, Collingham KE, Fegan CD, Milligan DW. Fulminant adenovirus hepatitis following unrelated bone marrow transplantation: failure of intravenous ribavirin therapy. Bone Marrow Transplant 1999; 23:1209-11.
27. Gavin PJ, Katz BZ. Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics 2002; 110:e9.
28. Ribaud P, Scieux C, Freymuth F, Morinet F, Gluckman E. Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin Infect Dis 1999; 28:690-1.
29. Bordigoni P, Carret AS, Venard V, Witz F, Le Faou A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2001; 32:1290-7.
30. Legrand F, Berrebi D, Houhou N, et al. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant 2001; 27:621-6.
31. Ljungman P, Ribaud P, Eyrich M, et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003; 31:481-6.
32. Lankester AC, Heemskerk B, Claas EC, et al. Effect of ribavirin on plasma viral DNA load in disseminating adenovirus infection. Clin Infect Dis 2004; 38:1521-5.
33. Echavarria M, Forman M, Ticehurst J, Dumler JS, Charache P. PCR method for detection of adenovirus in urine of healthy and human immunodeficiency virus-infected individuals. J Clin Microbiol 1998; 36:3323-6.
34. Claas ECJ, Schilham MW, de Brouwer CS, et al. Internally controlled real-time PCR monitoring of adenovirus DNA load in serum or plasma of transplant recipients. J Clin Microbiol [in press].
35. + adenovirus-specific T cells: implications for immunotherapy and gene therapy. J Virol 2003; 77:6562-6.
36. van der Burg SH, Ressing ME, Kwappenberg KM, et al. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 2001; 91:612-8.
37. de Jong A, van der Burg SH, Kwappenberg KM, et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002; 62:472-9.
38. Niesters HG, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus AD. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol 2000; 38:712-5.
39. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355:2032-6.
40. Niesters HG. Clinical virology in real time. J Clin Virol 2002; 25(Suppl3):S3-12.
41. Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7:388-94.
42. Gutierrez A, Munoz I, Solano C, et al. Reconstitution of lymphocyte populations and cytomegalovirus viremia or disease after allogeneic peripheral blood stem cell transplantation. J Med Virol 2003; 70:399-403.
43. Harvey BG, Hackett NR, El Sawy T, et al. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol 1999; 73:6729-42.
44. + T-cell responses from healthy adults. Viral Immunol 2001; 14:403-13.
45. + T cells in protection against CMV disease. Blood 2003; 101:2686-92.
46. Marshall NA, Howe JG, Formica R, et al. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000; 96:2814-21.
47. Smets F, Latinne D, Bazin H, et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002; 73:1603-10.
48. + T-cell epitope. Hum Gene Ther 2002; 13:1167-78.
49. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-44.
50. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 1997; 157:217-22.
51. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99:3916-22.
52. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002; 360:130-7.
53. Amrolia PJ, Muccioli-Casadei G, Yvon E, et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 2003; 102:2292-9.